Evidence map›Paper›PMID 34574981›Full record

ArticleHealthcare (Basel, Switzerland)2021

Factors Facilitating and Hindering Development of a Medication Use Review Service in Eastern Europe and Iran-Cross-Sectional Exploratory Study.

Anita Tuula, Daisy Volmer, Liisa Jõhvik, Ieva Rutkovska, Indre Trečiokienė, Piotr Merks, Magdalena Waszyk-Nowaczyk, Mariola Drozd, Alena Tatarević, Maja Radovanlija and 11 more

Open access · goldAbstract read
In one paragraph

Article in Healthcare (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 12 institutions in 9 countries.

Anita TuulaInstitute of Pharmacy, University of Tartu, 50411 Tartu, Estonia.ORCID 0000-0003-0682-4193
Daisy VolmerInstitute of Pharmacy, University of Tartu, 50411 Tartu, Estonia.ORCID 0000-0001-6742-5044
Liisa JõhvikHospital Pharmacy, Tartu University Hospital, 50406 Tartu, Estonia.
Ieva RutkovskaFaculty of Pharmacy, Riga Stradins University, LV-1007 Riga, Latvia.ORCID 0000-0003-4522-1803
Indre TrečiokienėPharmacy Center, Faculty of Medicine, Vilnius University, 01513 Vilnius, Lithuania.ORCID 0000-0001-6583-9999
Piotr MerksDepartment of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszyński University in Warsaw, 01-938 Warsaw, Poland.ORCID 0000-0001-8966-3799
Magdalena Waszyk-NowaczykDepartment of Pharmaceutical Technology, Pharmacy Practice Division, Poznan University of Medical Sciences, 60-780 Poznan, Poland.ORCID 0000-0001-6607-5126
Mariola DrozdDepartment of Humanities and Social Medicine, Medical University of Lublin, 20-093 Lublin, Poland.ORCID 0000-0002-1214-2386
Alena TatarevićIstrian Pharmacies, 52100 Pula, Croatia.
Maja RadovanlijaPharmacy Rajić, 34000 Požega, Croatia.
Carmen PacadiMandis Pharm Community Pharmacies, 10000 Zagreb, Croatia.
Arijana MeštrovićPharma Expert Consultancy and Education, 10040 Zagreb, Croatia.ORCID 0000-0002-9207-0027
Réka ViolaFaculty of Pharmacy, University of Szeged, H-6720 Szeged, Hungary.
Gyöngyvér SoósFaculty of Pharmacy, University of Szeged, H-6720 Szeged, Hungary.
Cristina RaisFaculty of Pharmacy, Carol Davila University of Medicine and Pharmacy, 020956 Bucharest, Romania.ORCID 0000-0003-2906-6794
Adriana-Elena TáerelFaculty of Pharmacy, Carol Davila University of Medicine and Pharmacy, 020956 Bucharest, Romania.ORCID 0000-0002-4451-1078
Magdalena KuzelovaDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, 83232 Bratislava, Slovakia.ORCID 0000-0003-0957-7554
Marziyeh ZareHealth Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz 7134845794, Iran.ORCID 0000-0002-3395-2337
Payam PeymaniRady Faculty of Health Sciences, College of Pharmacy, University of Manitoba, Winnipeg, MB R3E 0T5, Canada.
Marje OonaInstitute of Family Medicine and Public Health, University of Tartu, 50411 Tartu, Estonia.
Michael ScottMedicines Optimisation Innovation Centre, Antrim BT41 2RL, UK.ORCID 0000-0003-4048-0937
University of Tartu · EECarol Davila University of Medicine and Pharmacy · ROUniversity of Szeged · HUCardinal Stefan Wyszynski University in Warsaw · PLComenius University Bratislava · SKMedical University of Lublin · PLPoznan University of Medical Sciences · PLRiga Stradiņš University · LVShiraz University of Medical Sciences · IRTartu University Hospital · EEUniversity of Manitoba · CAVilnius University · LT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polypharmacy is a common issue in patients with chronic diseases. Eastern-European countries and Iran are exploring possibilities for implementing the Medication Use Review (MUR) as a measure for optimizing medication use and ensuring medication safety in polypharmacy patients. The aim of this study was to gain insights into the development of the community pharmacy sector and map facilitators and barriers of MUR in Eastern Europe and Iran. The representatives of the framework countries received a questionnaire on community pharmacy sector indicators, current and future developments of pharmacies, and factors encouraging and hindering MUR. To answer the questionnaire, all representatives performed document analysis, literature review, and qualitative interviews with key stakeholders. The socio-ecological model was used for inductive thematic analysis of the identified factors. Current community pharmacist competencies in framework countries were more related to traditional pharmacy services. Main facilitators of MUR were increase in polypharmacy and pharmaceutical waste, and access to patients' electronic list of medications by pharmacists. Main barriers included the service being unfamiliar, lack of funding and private consultation areas. Pharmacists in the framework countries are well-placed to provide MUR, however, the service needs more introduction and barriers mostly on organizational and public policy levels must be addressed.

Indexed as

barrierscommunity pharmacymedication reviewMURpharmacist

Identifiers

PMID34574981
PMCPMC8468572
OpenAlexW3199279085

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.